Focus: Sonoma Biotherapeutics is a cell therapy and gene therapy company headquartered in South San Francisco focused on developing novel immunotherapeutic treatments. The company is in early-stage clinical development with multiple Phase 1 programs.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Best suited for early-career or risk-tolerant professionals seeking equity upside in cell therapy; unsuitable if stability and near-term growth are priorities.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sonoma Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sonoma Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo